Relmada Therapeutics Revenue, Profits - RLMD Quarterly Income Statement

Add to My Stocks
$0.95 $0 (0%) RLMD stock closing price Sep 19, 2018 (Closing)

Looking at financial statements, along with the Relmada Therapeutics stock price, it's management, its economic moat, and industry competitors forms an important part of fundamental analysis. In the income statement, an investor can check for important parameters like the topline or sales, the bottomline or profits, the basic EPS, dividends etc. The income statement is always for an accounting period, typically for a year or quarter, and affects the stock. In this case, the RLMD stock is bound to reflect the impact of the QOQ decline of 0. One also needs to look at Relmada Therapeutics assets, operating expenses and Relmada Therapeutics free cash flow. The Relmada Therapeutics profit and loss statement shows revenue of $- for 2018 Q3. Revenue has decreased by 0 QoQ for RLMD stock.

View and download details of revenue and profits for Relmada Therapeutics for latest & last 40 quarters.
show more
Quarterly
Annual
View Previous Quarters
View Next Quarters
Fiscal year is Jul - Jun2018 Q32018 Q22018 Q12017 Q42017 Q32017 Q22017 Q12016 Q42016 Q32016 Q2
Relmada Therapeutics Revenues or Net Sales
----------
Cost Of Goods Sold (COGS)----------
Relmada Therapeutics Gross Profit
----------
Research & Development Expense1.66M--------2.11M
Selling General & Admin Expense-1.3M-1.6M1.79M1.28M1.25M2.51M2.13M3.6M
Income Before Depreciation Depletion Amortization-2.54M-1.45M-0.98M-1.79M-2.28M-1.53M-1.61M-3.13M-2.74M-5.72M
Depreciation Depletion Amortization----------
Non Operating Income-0.65M------0.02M-0.19M-3.26M
Interest Expense----------
Relmada Therapeutics Pretax Income
-3.2M-1.42M-0.98M-1.63M-1.98M-1.03M-1.64M-3.32M-1.85M-2.46M
Provision for Income Taxes----------
MinorityInterest----------
Investment Gains Losses----------
Other Income----------
Income Before Extraordinaries & Disc Operations-3.2M-1.42M-0.98M-1.63M-1.98M-1.03M-1.64M-3.32M-1.86M-2.46M
Extraordinary Items & Discontinued Operations----------
Relmada Therapeutics Profit/ Loss (Net Income)
-3.2M-1.42M-0.98M-1.63M-1.98M-1.03M-1.64M-3.32M-1.86M-2.46M
Average Shares used to compute Diluted EPS12.55M-12.53M-12.04M12.04M12.04M11.6M12M11.42M
Average Shares used to compute Basic EPS12.55M-12.53M-12.04M12.04M12.04M11.6M12M11.42M
Income Before Nonrecurring Items-3.2M--0.98M--1.98M-1.03M-1.64M-3.32M-1.86M-2.46M
Income from Nonrecurring Items----------
Relmada Therapeutics Earnings Per Share Basic Net
-0.26-0.11-0.08--0.16-0.09-0.14-0.29-0.15-0.22
Relmada Therapeutics Earnings Per Share Diluted Net
-0.26-0.11-0.08--0.16-0.09-0.14-0.29-0.15-0.22
EPS Diluted Before Nonrecurring Items-0.26--0.08--0.16-0.09-0.14-0.29-0.15-0.22
Preferred Dividends Acc Pd----------
Dividends Common0.000.00--------
Dividend Per Share Common0.000.000.000.000.000.000.000.000.000.00
All figures in USD. M: Millions of USD, B: Billions of USD.
View Previous Quarters
View Next Quarters

The key things to look for in an income statement while doing Relmada Therapeutics stock analysis are:

  • Top line: The word topline comes from the fact that the first line of an income statement refers to sales numbers. If you check you will find that RLMD stock has a topline or revenue of $- for 2018 Q3 as per this Relmada Therapeutics revenue chart. Investors look for stocks with a growing top line.
  • Bottom line: The bottomline or the net income figure is arrived at by deducting all expenses from the topline which in this case is $-3.2M for RLMD stock. An improving bottomline implies that the company is growing its profits.

The income statement is also called statement of revenue and expense. The RLMD financials along with Relmada Therapeutics historical stock prices provide a lot of details about the firm.

Relmada Therapeutics Income Statement - Key Financial Ratios